BIOA
BioAge Labs Inc. · NASDAQ
- Market cap
- $255.1M
BioAge Labs Inc. (BIOA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for BIOA, including 3 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 11, 2026.
BIOA rankings
Financial highlights
Full financials- Revenue, TTM
- $8.60M
- Revenue growth
- +45.3%
- Net income, TTM
- -$107.80M
- Net margin
- -1253.6%
- Free cash flow, TTM
- -$103.00M
- Cash
- $52.67M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks28+100%
2026-05-242026-11-15
Mix1390d
- Other8(62%)
- SEC Filings3(23%)
- Analyst1(8%)
- Earnings1(8%)
Activity · 52 weeks9055 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRBioAge Labs to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Stifel NYC Healthcare Conference (New York, November 10–12, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on Thursday, November 12 from 1:20 PM to 1:50 PM EST. BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will parti
- SECSEC Form 10-Q filed by BioAge Labs Inc.10-Q - BioAge Labs, Inc. (0001709941) (Filer)
- SECBioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioAge Labs, Inc. (0001709941) (Filer)
- PRBioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesFirst participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated baseline inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026 APJ agonist program, an exercise-mimetic approach to obesity, on track for IND submission by year-end 2026 EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for ca
- PRBioArctic collaborator Novartis terminates agreementSTOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Novartis proprietary antibody. The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology.BioArctic will retain the full USD 30 million upfront payment and, as a result of the termination, will recognize the remaining unrecognized portion as reve
- PRBioArctic's Nomination Committee appointedSTOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has been appointed in accordance with the principles adopted by the Annual General Meeting and consists of representatives of the three largest shareholders by voting rights as of September 30, 2026, as well as the Chair of the Board (convener).The Nomination Committee comprises the following members:Margareta Öhrvall, appointed by Demban ABPär Gellerfors, appointed by Ackelsta ABThomas Ehlin, Chair of the Nomination Committee, representing Fjärde AP-fondenAs of September 30, 2026,
- PRDeep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First TargetSOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The collaboration has reached its first milestone: novel small-molecule hits identified computationally by Deep Origin against a novel BioAge target have been validated in BioAge’s wet lab. The collaboration aims to speed drug development against novel targets by utilizing hybrid AI and physics-based models for computational drug discovery. Under the agreem
- ANALYSTUBS initiated coverage on BioAge Labs with a new price targetUBS initiated coverage of BioAge Labs with a rating of Neutral and set a new price target of $8.00
- SECBioAge Labs Inc. filed SEC Form 8-K: Other Events8-K - BioAge Labs, Inc. (0001709941) (Filer)
- PRBioAge Labs to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. • Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is
- PRBioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular EdemaRandomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first particip
- PRBioAge Labs to Present at Upcoming Investor ConferencesEMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi Biopharma Back to School Conference (New York, September 9–10, 2026): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Wednesday, September 9 at 11:20–11:55 AM EDT. Kristen Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the pr
- PRNumber of shares and votes in BioArctic AB (publ) as of August 31, 2026STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 20,200 stock options of series 2019/2028. As of August 31, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,744,685 shares, of which 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)
- SECSEC Form 10-Q filed by BioAge Labs Inc.10-Q - BioAge Labs, Inc. (0001709941) (Filer)
- SECBioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioAge Labs, Inc. (0001709941) (Filer)
- PRBioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesFirst participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-2027; results expected to support development across inflammation-driven retinal diseases Hosted R&D Day focused on NLRP3 inhibition, featuring Phase 1 data for BGE-102 EMERYVILLE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or "the Company"), a clinical-stage biopharmaceutical company developing therapeut
- PRMore than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype. The data were presented during the session "Developing Topics Session #3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Al
- INSIDERPrincipal Accounting Officer Barton Shane exercised 59,934 shares at a strike of $6.58 and sold $1,576,752 worth of shares (62,566 units at $25.20) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - BioAge Labs, Inc. (0001709941) (Issuer)
- PRBioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskRandomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinic
- INSIDERSEC Form 4 filed by Director Pande Vijay Satyanand4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Director Hemrajani Rekha4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Director Healy James4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Director Enright Patrick G4 - BioAge Labs, Inc. (0001709941) (Issuer)
- INSIDERSEC Form 4 filed by Director Davidson Michael H.4 - BioAge Labs, Inc. (0001709941) (Issuer)
BIOA FAQ
10 questionsWhat is the latest news on BIOA?
In the last 30 days Quantisnow tracked 6 wire items for BIOA: 3 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published on November 11, 2026.What is BIOA revenue?
BioAge Labs Inc. (BIOA) reported $8.60M of revenue for the twelve months ended Sep 30, 2026. That is up 45.3% from the year before. Revenue for fiscal 2025 was $8.99M.Is BIOA profitable?
No. BioAge Labs Inc. reported a net loss of $107.80M for the twelve months ended Sep 30, 2026.How much cash and debt does BIOA have?
BioAge Labs Inc. reported $52.67M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BIOA stock trade?
BioAge Labs Inc. (BIOA) is listed on NASDAQ.What sector and industry is BIOA in?
BioAge Labs Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BioAge Labs Inc. go public?
BioAge Labs Inc. (BIOA) completed its IPO in 2024.What are analysts saying about BIOA?
Across the last 8 analyst actions on BioAge Labs Inc., there were 2 upgrades and 0 downgrades. The most recent action was from UBS: Neutral with a $8.00 price target on 2026-10-12.What companies are similar to BIOA?
Notable peers in the same industry include NVO (Novo Nordisk A/S), NVS (Novartis AG), LLY (Eli Lilly and Company). Compare BIOA side-by-side with any of them on Quantisnow.How can I track BIOA on Quantisnow?
Quantisnow aggregates BioAge Labs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIOA to receive live email and push alerts on every new disclosure.